Ga-68 PSMA PET-CT
On this page
Direct answer
Ga-68 PSMA PET-CT images prostate cancer by targeting prostate-specific membrane antigen, a transmembrane folate hydrolase overexpressed on prostate cancer cells, with a gallium-68-labelled small ligand whose uptake is read on diagnostic CT. Its two strong indications are biochemical recurrence after surgery or radiotherapy, where detection rises steeply with PSA — roughly under half of scans find disease when PSA is below 0.5 ng/mL but the large majority do above 2 ng/mL — and primary staging of high-risk or aggressive disease (PSA above 20, Gleason 8-10, or clinical T3). Because gallium-68 has a half-life of only 68 minutes, it is supplied from a germanium-68 generator on site or from a cyclotron radiopharmacy, and the same targeting logic extends to Lu-177-labelled PSMA therapy in metastatic castration-resistant disease.
What you must remember
- Tracer logic: PSMA ligands bind cell-surface PSMA and internalise; uptake is not prostate-specific — physiological uptake in salivary and lacrimal glands, liver, spleen, kidneys and bowel is expected and must not be called disease.
- Detection versus PSA (recurrence setting): detection rises from roughly 40-60 per cent below 0.5 ng/mL to the large majority above 2 ng/mL; higher PSA velocity and Gleason grade further improve yield, so the test is best timed when PSA is rising but salvage treatment is still possible.
- Primary staging: for high-risk prostate cancer, PSMA PET outperforms conventional CT and bone scan for nodal and bone disease, changing management in a meaningful minority.
- Pitfalls: PSMA-avid non-prostate cancers (renal cell, urothelial, thyroid) and benign mimics (Paget disease, healing fractures, schwannoma and other nerve sheath tumours) can light up; bladder excretion hides the prostate bed unless read carefully.
- Radionuclide physics: Ga-68 half-life 68 minutes, generator-produced (Ge-68 parent), positron energy suited to PET; F-18 alternatives (fluciclovine, DCFPyL) have a 110-minute half-life allowing central production and distribution.
- Therapy bridge: Lu-177-PSMA radioligand therapy delivers beta radiation to PSMA-avid lesions in metastatic castration-resistant prostate cancer, with trials showing improved survival where indicated.
One scan, one management fork
A 66-year-old had a radical prostatectomy three years ago. His PSA has climbed from 0.2 to 1.8 ng/mL over six months. Guideline imaging before salvage therapy is now Ga-68 PSMA PET-CT. The scan shows a small intense focus in the right pelvic side wall — a node conventional CT called normal — with no bone uptake elsewhere; physiological tracer in the salivary glands, liver and kidneys is ignored, and the bladder void is read around. Management changes: instead of blind salvage radiotherapy to the prostate bed alone, the node is included in the field. Had the scan shown widespread skeletal uptake, the fork turns systemic instead — the point of the test is to localise recurrence precisely enough to choose curative-intent local therapy or systemic treatment.
Contrast this with a newly diagnosed 58-year-old with a PSA of 90 and Gleason 9: PSMA PET-CT at primary staging shows two iliac nodes and a lumbar deposit, upstaging him from presumed localised disease and directing androgen deprivation with radiotherapy fields planned around the metabolic map.
Where students slip
The commonest slip is calling every hotspot metastasis: physiological uptake in salivary glands and kidneys is normal, and degenerative or healing bone uptake must be correlated with CT morphology — hybrid reporting means reading the CT half, not just the coloured map. The second slip is the timing question: scanning too early after prostatectomy (PSA under 0.2 ng/mL) yields little, and the exam expects the PSA-threshold reasoning rather than "do a PSMA PET always". Third, physics: candidates confuse Ga-68 generator supply with F-18 cyclotron supply, and the viva asks precisely why a hospital without a cyclotron can still run Ga-68 PSMA — the 68-minute half-life is workable on site from a generator, while F-18's 110 minutes permit regional distribution. In India, access concentrates in metropolitan centres with generators or cyclotron radiopharmacies, and public-sector availability is expanding; the exam answer should acknowledge the tiered reality while stating the indications firmly.
Frequently asked questions
What is PSMA and why is it a prostate cancer target?
Prostate-specific membrane antigen is a folate hydrolase overexpressed on prostate cancer cells; radiolabelled ligands bind and internalise in it, making tumour uptake highly sensitive for disease localisation.
How does PSA level affect Ga-68 PSMA detection in recurrence?
Detection is roughly 40-60 per cent when PSA is below 0.5 ng/mL and rises to the large majority above 2 ng/mL, so timing the scan with a rising PSA improves yield.
Which non-prostate tissues and tumours show physiological or misleading PSMA uptake?
Salivary and lacrimal glands, liver, spleen, kidneys and bowel take up tracer physiologically, while renal cell, urothelial and thyroid cancers and some benign lesions can mimic disease.
Why can Ga-68 PSMA be performed without a cyclotron?
Gallium-68 is eluted from a long-lived germanium-68 generator on site, and its 68-minute half-life suits local use, unlike fluorine-18's 110-minute half-life from a central cyclotron.
What is Lu-177 PSMA therapy?
Radioligand therapy delivering beta-emitting lutetium-177 bound to the same PSMA-targeting molecule, used for PSMA-avid metastatic castration-resistant prostate cancer after standard treatments.